目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T74625 | |||
HCV-IN-41 (compound 4) 是一种高效的丙肝病毒 (HCV)抑制剂,对 HCV1b、2a、3a 和 4a 的 EC50分别为 0.006762 nM、5.183 nM、1.365 nM 和 142.2 nM。HCV-IN-41 能降低 HCVRNA 的复制。 | |||
T6025 | HCV Protease SARS-CoV | ||
Danoprevir (RG7227) 是具有口服活性的NS3/4A 蛋白酶抑制剂,IC50值为 0.29 nM。它抑制 HCV 基因型 1a, 1b, 4, 5, 6 (IC50s=0.2-0.4 nM) 和 2b, 3a (IC50s=1.6, 3.5 nM)。它也是SARS-CoV 3CLpro 的抑制剂,IC50为 0.05 μM。 | |||
T3001 | ERK HCV Protease MEK Akt Autophagy | ||
Honokiol (NSC-293100) 是厚朴提取物的活性成分,靶向多种信号分子,具有抗氧化,抗炎,抗血管生成和抗癌活性。它可抑制 Akt 的激活并增强 ERK1/ERK2 的磷酸化。 | |||
T9331 | HCV Protease SARS-CoV | ||
Bemnifosbuvir hemisulfate (AT-527) 是一种 HCV 病毒复制抑制剂。 | |||
T76518 | |||
HCVPeptide (131-140) 是一种肽。HCVPeptide (131-140) 可用于丙型肝炎病毒(HCV)的研究。 | |||
T9518 | HBV | ||
Inarigivir ammonium (SB-9200 ammonium) 是一种二核苷酸抗病毒化合物,可显着降低表达乙型肝炎病毒的转基因小鼠的 HBV DNA。它是一种激活细胞内先天免疫的视黄酸诱导基因-I 激动剂。 | |||
T6200 | HCV Protease SARS-CoV | ||
Ledipasvir (GS-5885) 是一种丙型肝炎病毒 NS5A 抑制剂。它也是 P-糖蛋白抑制剂和乳腺癌抗性蛋白抑制剂。 | |||
TQ0064 | HCV Protease Retinoid Receptor S1P Receptor Autophagy | ||
Peretinoin (NIK333) 是口服非环状类视黄醇,靶向类视黄醇核受体,结构类维生素 A 。 | |||
T19073 | HCV Protease | ||
Tris(4-aminophenyl)methane (Leucopararosaniline) 是一种三苯甲烷类染料,是一种 HCV 解旋酶抑制剂。 | |||
T7607 | HCV Protease | ||
PSI-6130 (R 1656) 是高效选择性 HCV NS5B 聚合酶抑制剂,抑制 HCV 复制,IC50值为 0.6 μM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01564 | Hepatitis C virus (HCV-1a) E2 Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus (HCV-1a) E2 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 32 kDa and the accession number is NP_751921.1.
|
|||||
TMPY-00296 | Hepatitis C virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 32.2 kDa and the accession number is BAA03581.1.
|
|||||
TMPY-04135 | Hepatitis C virus Envelope Glycoprotein E1/HCV-E1 (subtype 1b, strain HC-J4) Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus Envelope Glycoprotein E1/HCV-E1 (subtype 1b, strain HC-J4) Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.7 kDa and the accession number is AAC15725.1.
|
|||||
TMPY-05166 | Hepatitis C virus (HCV) (serotype 1b, isolate HC-J4) Envelope/E2 Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus (HCV) (serotype 1b, isolate HC-J4) Envelope/E2 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 32.4 kDa and the accession number is AAC15723.1.
|
|||||
TMPY-00323 | Hepatitis C virus (HCV-1a) NS3 protease/helicase immunodominant region Protein (aa 1356-1459, GST) | HCV | E. coli | ||
HCV NS3 displays three enzymatic activities: serine protease, NTPase, and RNA helicase. HCV NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B. HCV NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. One of the HCV proteases, NS3-4A serine protease, is a non-covalent heterodimer consisting of a catalytic subunit (the N-terminal one-third of NS3 protein) and an activating cofactor (NS4A protein) and is responsible for cleavage at four sites of the HCV polyprotein.
|
|||||
TMPJ-01273 | ACY3 Protein, Human, Recombinant (His) | Human | E. coli | ||
Aspartoacylase 3, also known as ACY3, N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming), Acylase III, Aminoacylase-3, Aspartoacylase-2, Aspartoacylase-2, HCV core-binding protein 1 and ASPA2, is a member of the Aspartoacylase subfamily. ACY3 plays an important role in deacetylating mercapturic acids in kidney proximal tubules and acts on N-acetyl-aromatic amino acids.ACY3 is located in the cytoplasm of S2 and S3 proximal tubules and the apical domain of S1 proximal tubules. ACY3 protein is also expressed at low levels in stomach, testis, heart, brain, lung and liver, and may function as an HCV (Hepatitis C virus) core binding protein.
|
|||||
TMPY-02285 | Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Non-structural/NS2 Protein | H1N1 | E. coli | ||
Non-structural protein 2 (NS2) plays a crucial role in the hepatitis C virus (HCV) assembly. NS2 was predicted to be composed of three transmembrane (TM) segments. Hepatitis C virus (HCV) nonstructural protein 2 (NS2) is a hydrophobic, transmembrane protein that is required not only for NS2-NS3 cleavage but also for infectious virus production.NS2 protein is essential for hepatitis C virus (HCV) replication. NS2 protein was expressed and purified. Aptamers against NS2 protein were raised and antiviral effects of the aptamers were examined. The non-structural protein NS2, also called nuclear export protein, of influenza A virus contains a leucine-rich nuclear export signal that could guide viral ribonucleoproteins to cross the nuclear pore complex (NPC) and complete directional nucleocytoplasmic trafficking.
|
|||||
TMPH-01548 | IFI6 Protein, Human, Recombinant (B2M & His) | Human | E. coli | ||
Plays a role in apoptosis, negatively regulating the intrinsinc apoptotic signaling pathway and TNFSF10-induced apoptosis. However, it has also been shown to have a pro-apoptotic activity. Has an antiviral activity towards hepatitis C virus/HCV by inhibiting the EGFR signaling pathway, which activation is required for entry of the virus into cells.
|
|||||
TMPH-00848 | OASL Protein, Human, Recombinant (His) | Human | E. coli | ||
Does not have 2'-5'-OAS activity, but can bind double-stranded RNA. Displays antiviral activity against encephalomyocarditis virus (EMCV) and hepatitis C virus (HCV) via an alternative antiviral pathway independent of RNase L. OASL Protein, Human, Recombinant (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 65.1 kDa and the accession number is Q15646.
|
|||||
TMPH-01104 | Claudin-9 Protein-VLP, Human, Recombinant (His) | Human | HEK293 Cells | ||
Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells. Claudin-9 Protein-VLP, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-10xHis tag. The predicted molecular weight is 24.2 kDa and the accession number is O95484.
|
|||||
TMPH-01248 | ADAR Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.
|
|||||
TMPH-00809 | Hepatitis C Genome polyprotein (His) | HCV | E. coli | ||
Hepatitis C Genome polyprotein (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 71.3 kDa and the accession number is S4UAW6.
|
|||||
TMPJ-01330 | CD299 Protein, Human, Recombinant (His & Flag) | Human | HEK293 Cells | ||
CD299 is also known as DC-SIGNR and CLEC4M, is a type II integral membrane protein. DC-SIGNR exists as a homotetramer, and the tandem repeat domain, also called neck domain, mediates oligermerization. Multiple human DC-SIGN/CD209 splice forms exist, generating both membrane-bound and soluble forms. DC-SIGNR is ragarded as a pathogen-recognition receptor involved in peripheral immune surveillance in liver, and probably mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. DC-SIGNR appears to selectively recognize and bind many viral surface glycoproteins containing high mannose N-linked oligosaccharides in a calcium-dependent manner, including HIV-1 gp12, HIV-2 gp12, SIV gp12, ebolavirus glycoproteins, HCV E2, and human SARS coronavirus protein S, as well as the cellular adhesion protein ICAM3. DC-SIGN/CD209 is expressed on dendritic cells (DC) and inflammatory macrophages and contributes to antigen presentation.
|
|||||
TMPY-02193 | GOLPH2/GOLM1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Golgi membrane protein 1, also known as Golgi membrane protein GP73, Golgi phosphoprotein 2, and GOLM1, is a protein that belongs to the GOLM1 / CASC4 family. GOLM1 is widely expressed. It is highly expressed in the colon, prostate, trachea, and stomach. It is expressed at a lower level in testis, muscle, lymphoid tissues, white blood cells, and spleen. It is predominantly expressed by cells of the epithelial lineage. GOLM1 is expressed at a low level in the normal liver. Expression significantly increases in virus (HBV, HCV) infected liver. Expression of GOLM1 does not increase in liver disease due to non-viral causes (alcohol-induced liver disease, autoimmune hepatitis). Increased expression in hepatocytes appears to be a general feature of advanced liver disease. In liver tissue from patients with adult giant-cell hepatitis (GCH), GOLM1 is strongly expressed in hepatocyte-derived syncytial giant cells. GOLM1 is constitutively expressed by biliary epithelial cells but not by hepatocytes.
|